Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
COO | Kura OncologyKURA | Open-market sale10b5-1 plan | 09/28–09/29 | 09/29 | 10,574 sh2 trades | $10.59avg. | $111,931.22 | −6.9% |
Kura OncologyKURA | Open-market sale | 09/28–09/29 | 09/29 | 32,450 sh3 trades | $10.63avg. | $345,035.69 | −19.2% | |
Chief Medical Officer | Kura OncologyKURA | Open-market sale | 09/28–09/29 | 09/29 | 41,250 sh2 trades | $10.67avg. | $440,237.17 | −22.6% |
Bair Teresa BrophyChief Legal Officer | Kura OncologyKURA | Open-market sale10b5-1 plan | 09/28 | 09/29 | 8,442 sh | $10.50 | $88,618.21 | −4.3% |
Doyle Thomas JamesSVP, Finance & Accounting | Kura OncologyKURA | Open-market sale | 09/28 | 09/29 | 4,607 sh | $10.50 | $48,360.6 | −3.1% |
Francis BurrowsChief Scientific Officer | Kura OncologyKURA | Open-market sale | 09/24 | 09/25 | 20,726 sh | $10.83 | $224,514.4 | −32.9% |
Mollie LeoniChief Medical Officer | Kura OncologyKURA | Open-market sale10b5-1 plan | 06/18 | 06/22 | 84,929 sh | $9.82 | $834,002.78 | −31.8% |
Powl Brian T.Chief Commercial Officer | Kura OncologyKURA | Open-market sale10b5-1 plan | 05/21 | 05/22 | 10,000 sh | $11.00 | $110,000 | −5.4% |
Kura OncologyKURA | Open-market sale10b5-1 plan | 05/19 | 05/20 | 2,257 sh | $9.08 | $20,493.56 | −1.4% | |
Powl Brian T.Chief Commercial Officer | Kura OncologyKURA | Open-market sale10b5-1 plan | 05/19 | 05/20 | 339 sh | $9.21 | $3,122.19 | −0.2% |
Bair Teresa BrophyChief Legal Officer | Kura OncologyKURA | Open-market sale10b5-1 plan | 05/18 | 05/20 | 2,256 sh | $9.38 | $21,161.28 | −1.0% |
Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 1,813 sh | $8.46 | $15,337.98 | −1.2% | |
Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 11,208 sh3 trades | $8.46avg. | $94,819.68 | −4.7% | |
SVP, Finance & Accounting | Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 7,142 sh5 trades | $8.46avg. | $60,421.32 | −4.7% |
Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 6,414 sh2 trades | $8.46avg. | $54,262.44 | −3.4% | |
Chief Medical Officer | Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 8,180 sh4 trades | $8.46avg. | $69,202.8 | −3.0% |
Francis BurrowsChief Scientific Officer | Kura OncologyKURA | Open-market sale | 01/27 | 01/27 | 1,311 sh | $8.46 | $11,091.06 | −3.9% |
Francis BurrowsChief Scientific Officer | Kura OncologyKURA | Open-market sale | 25/12/18 | 25/12/19 | 23,726 sh | $9.78 | $232,040.28 | −41.3% |
Faheem HasnainDirector | Kura OncologyKURA | Open-market sale | 25/12/09 | 25/12/10 | 10,000 sh | $10.98 | $109,800 | −29.4% |
Kura OncologyKURA | Open-market sale10b5-1 plan | 25/11/14 | 25/11/14 | 6,902 sh | $11.18 | $77,164.36 | −6.1% |
